Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry.
Atrial secondary tricuspid regurgitation
Transcatheter edge-to-edge repair
Transcatheter tricuspid valve interventions
Ventricular secondary tricuspid regurgitation
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
revised:
19
09
2023
received:
14
05
2023
accepted:
24
10
2023
pubmed:
31
10
2023
medline:
31
10
2023
entrez:
31
10
2023
Statut:
aheadofprint
Résumé
Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. Data on tricuspid transcatheter edge-to-edge repair (T-TEER) in patients with STR according to phenotype (i.e. ASTR vs. VSTR) are lacking. The aim of this study was to assess characteristics and outcomes of patients with ASTR versus VSTR undergoing T-TEER. Patients with STR undergoing T-TEER were selected from the Transcatheter Tricuspid Valve Therapies (TriValve) registry. ASTR was defined by (i) left ventricular ejection fraction ≥50%, (ii) atrial fibrillation, and (iii) systolic pulmonary artery pressure <50 mmHg. Patients not matching these criteria were classified as VSTR. Patients with primary TR and cardiac implantable electronic device were excluded. Key endpoints included procedural success and survival at follow-up. A total of 298 patients were enrolled in the study: 65 (22%) with ASTR and 233 (78%) with VSTR. Procedural success was similar in the two groups (80% vs. 83% for ASTR vs. VSTR, p = 0.56) and TEER was effective in reducing TR in both groups (from 97% of patients with baseline TR ≥3+ to 23% in ASTR and to 15% in VSTR, all p = 0.001). At 12-month follow-up, survival was significantly higher in the ASTR versus VSTR cohort (91% vs. 72%, log-rank p = 0.02), with VSTR being an independent predictor of mortality at multivariable analysis (hazard ratio 4.75). In a real-world, multicentre registry, T-TEER was effective in reducing TR grade in both ASTR and VSTR. At 12-month follow-up, ASTR showed better survival than VSTR.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 European Society of Cardiology.
Références
Rodés-Cabau J, Taramasso M, O'Gara PT. Diagnosis and treatment of tricuspid valve disease: Current and future perspectives. Lancet 2016;388:2431-2442. https://doi.org/10.1016/S0140-6736(16)00740-6
Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 2019;74:2998-3008. https://doi.org/10.1016/j.jacc.2019.09.028
Benfari G, Antoine C, Miller WL, Thapa P, Topilsky Y, Rossi A, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation 2019;140:196-206. https://doi.org/10.1161/CIRCULATIONAHA.118.038946
Messika-Zeitoun D, Verta P, Gregson J, Pocock SJ, Boero I, Feldman TE, et al. Impact of tricuspid regurgitation on survival in patients with heart failure: A large electronic health record patient-level database analysis. Eur J Heart Fail 2020;22:1803-1813. https://doi.org/10.1002/ejhf.1830
Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004;43:405-409. https://doi.org/10.1016/j.jacc.2003.09.036
Scotti A, Coisne A, Taramasso M, Granada JF, Ludwig S, Rodés-Cabau J, et al. Sex-related characteristics and short-term outcomes of patients undergoing transcatheter tricuspid valve intervention for tricuspid regurgitation. Eur Heart J 2023;44:822-832. https://doi.org/10.1093/eurheartj/ehac735
Heitzinger G, Pavo N, Koschatko S, Jantsch C, Winter MP, Spinka G, et al. Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum. Eur J Heart Fail 2023;25:857-867. https://doi.org/10.1002/ejhf.2858
Russo G, Taramasso M, Pedicino D, Gennari M, Gavazzoni M, Pozzoli A, et al. Challenges and future perspectives of transcatheter tricuspid valve interventions: Adopt old strategies or adapt to new opportunities? Eur J Heart Fail 2022;24:442-454. https://doi.org/10.1002/ejhf.2398
Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention 2021;17:791-808. https://doi.org/10.4244/EIJ-D-21-00695
Muraru D, Guta AC, Ochoa-Jimenez RC, Bartos D, Aruta P, Mihaila S, et al. Functional regurgitation of atrioventricular valves and atrial fibrillation: An elusive pathophysiological link deserving further attention. J Am Soc Echocardiogr 2020;33:42-53. https://doi.org/10.1016/j.echo.2019.08.016
Gavazzoni M, Heilbron F, Badano LP, Radu N, Cascella A, Tomaselli M, et al. The atrial secondary tricuspid regurgitation is associated to more favorable outcome than the ventricular phenotype. Front Cardiovasc Med 2022;9:1022755. https://doi.org/10.3389/fcvm.2022.1022755
Florescu DR, Muraru D, Volpato V, Gavazzoni M, Caravita S, Tomaselli M, et al. Atrial functional tricuspid regurgitation as a distinct pathophysiological and clinical entity: No idiopathic tricuspid regurgitation anymore. J Clin Med 2022;11:382. https://doi.org/10.3390/jcm11020382
Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 2019;12:433-442. https://doi.org/10.1016/j.jcmg.2018.06.014
Florescu DR, Muraru D, Florescu C, Volpato V, Caravita S, Perger E, et al. Right heart chambers geometry and function in patients with the atrial and the ventricular phenotypes of functional tricuspid regurgitation. Eur Heart J Cardiovasc Imaging 2022;23:930-940. https://doi.org/10.1093/ehjci/jeab211
Mutlak D, Lessick J, Reisner SA, Aronson D, Dabbah S, Agmon Y. Echocardiography-based spectrum of severe tricuspid regurgitation: The frequency of apparently idiopathic tricuspid regurgitation. J Am Soc Echocardiogr 2007;20:405-408. https://doi.org/10.1016/j.echo.2006.09.013
Schlotter F, Dietz MF, Stolz L, Kresoja KP, Besler C, Sannino A, et al. Atrial functional tricuspid regurgitation: Novel definition and impact on prognosis. Circ Cardiovasc Interv 2022;15:e011958. https://doi.org/10.1161/CIRCINTERVENTIONS.122.011958
Topilsky Y, Nkomo VT, Vatury O, Michelena HI, Letourneau T, Suri RM, et al. Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging 2014;7:1185-1194. https://doi.org/10.1016/j.jcmg.2014.07.018
Lancellotti P, Pibarot P, Chambers J, La Canna G, Pepi M, Dulgheru R, et al.; Scientific Document Committee of the European Association of Cardiovascular Imaging. Multi-modality imaging assessment of native valvular regurgitation: An EACVI and ESC Council of Valvular Heart Disease position paper. Eur Heart J Cardiovasc Imaging 2022;23:e171-e232. https://doi.org/10.1093/ehjci/jeab253
Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: A report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30:303-371. https://doi.org/10.1016/j.echo.2017.01.007
Dreyfus J, Audureau E, Bohbot Y, Coisne A, Lavie-Badie Y, Bouchery M, et al. TRI-SCORE: A new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery. Eur Heart J 2022;43:654-662. https://doi.org/10.1093/eurheartj/ehab679
Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297-3317. https://doi.org/10.1093/eurheartj/ehz641
Dreyfus J, Galloo X, Taramasso M, Heitzinger G, Benfari G, Kresoja KP, et al. TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation. Eur Heart J. https://doi.org/10.1093/eurheartj/ehad585 Published online ahead of print 25/08/23.
Bisbal F, Baranchuk A, Braunwald E, Bayés de Luna A, Bayés-Genís A. Atrial failure as a clinical entity: JACC review topic of the week. J Am Coll Cardiol 2020;75:222-232. https://doi.org/10.1016/j.jacc.2019.11.013
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4-131. https://doi.org/10.1002/ejhf.2333
Patlolla SH, Schaff HV, Nishimura RA, Stulak JM, Chamberlain AM, Pislaru SV, et al. Incidence and burden of tricuspid regurgitation in patients with atrial fibrillation. J Am Coll Cardiol 2022;80:2289-2298. https://doi.org/10.1016/j.jacc.2022.09.045
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561-632. https://doi.org/10.1093/eurheartj/ehab395
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC Focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252-289. https://doi.org/10.1016/j.jacc.2017.03.011
Galloo X, Dietz MF, Fortuni F, Prihadi EA, Cosyns B, Delgado V, et al. Prognostic implications of atrial vs. ventricular functional tricuspid regurgitation. Eur Heart J Cardiovasc. Imaging 2023;24:733-741. https://doi.org/10.1093/ehjci/jead016
Doldi P, Stolz L, Orban M, Karam N, Praz F, Kalbacher D, et al. Transcatheter mitral valve repair in patients with atrial functional mitral regurgitation. JACC Cardiovasc Imaging 2022;15:1843-1851. https://doi.org/10.1016/j.jcmg.2022.05.009
Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol 2023;81:1810-1834. https://doi.org/10.1016/j.jacc.2023.01.049
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017;19:1574-1585. https://doi.org/10.1002/ejhf.813
Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al.; TRILUMINATE Pivotal Investigators. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med 2023. https://doi.org/10.1056/NEJMoa2300525. 388, 1833-1842.
Unterhuber M, Kresoja KP, Besler C, Rommel KP, Orban M, von Roeder M, et al. Cardiac output states in patients with severe functional tricuspid regurgitation: Impact on treatment success and prognosis. Eur J Heart Fail 2021;23:1784-1794. https://doi.org/10.1002/ejhf.2307
Kresoja KP, Lauten A, Orban M, Rommel KP, Alushi B, Besler C, et al. Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction. Eur J Heart Fail 2020;22:1817-1825. https://doi.org/10.1002/ejhf.1975